Updates are available Correction dated 2023-05-29
Click to view Correction: https://doi.org/10.1007/s12519-023-00724-8
-
Authors
Vodicska, Barbara https://orcid.org/0000-0003-1191-234X
Déri, Júlia
Tihanyi, Dóra
Várkondi, Edit
Kispéter, Enikő
Dóczi, Róbert
Lakatos, Dóra
Dirner, Anna
Vidermann, Mátyás
Filotás, Péter
Szalkai-Dénes, Réka
Szegedi, István
Bartyik, Katalin
Gábor, Krisztina Míta
Simon, Réka
Hauser, Péter
Péter, György
Kiss, Csongor
Garami, Miklós
Peták, István
-
Funding
Funding for this research was provided by:
Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (KFI_16-1-2016-0048, 2019-1.1.1-PIACI-KFI-2019-00367, NKFIH K_22 143021)
National Research, Development and Innovation Office (NVKP_16-1-2016-0005)
Semmelweis University
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 31 January 2023
First Online: 13 March 2023
Change Date: 29 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12519-023-00724-8
Declarations
:
: IP is an employee and equity holder in Oncompass Medicine Inc., and Genomate Health Inc. BV, JD, DT, EK, RD, DL, AD, MV, EV, PF, RSZ-D are employees of Oncompass Medicine Inc. All other authors declare no conflict interests.
: Participants or their parents or legal guardian signed consent for study participation after risks and benefits had been explained. Consents extend to the purposes of the study, the limitations of the tests and the understanding and approval of data storage, data analysis and management. Ethics approval was obtained from the National Institute of Pharmacy and Nutrition (OGYÉI/50268/2017) before conducting the study.
